REMARKS

The specification has been amended to reflect the national stage status.

In addition, the claims have been amended to remove multiple dependencies in order to reduce the PTO filing fee.

Additional amendments have been made to place the application in conformance with U.S. practice, such as the addition of a pharmaceutically acceptable carrier to the composition claims, which is supported on pages 59-66.

Favorable action on the merits is solicited.

Respectfully submitted,

Hiromu HABASHITA et al.

Bv

Warren M. Cheek, Jr. Registration No. 33,367

Wardeeles

Attorney for Applicants

WMC/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 June 22, 2006